The Impact of 3D Models on Positive Surgical Margins After Robot-assisted Radical Prostatectomy
Overview
Authors
Affiliations
Purpose: To evaluate the role of 3D models on positive surgical margin rate (PSM) rate in patients who underwent robot-assisted radical prostatectomy (RARP) compared to a no-3D control group. Secondarily, we evaluated the postoperative functional and oncological outcomes.
Methods: Prospective study enrolling patients with localized prostate cancer (PCa) undergoing RARP with mp-MRI-based 3D model reconstruction, displayed in a cognitive or augmented-reality fashion, at our Centre from 01/2016 to 01/2020. A control no-3D group was extracted from the last two years of our Institutional RARP database. PSMr between the two groups was evaluated and multivariable linear regression (MLR) models were applied. Finally, Kaplan-Meier estimator was used to calculate biochemical recurrence at 12 months after the intervention.
Results: 160 patients were enrolled in the 3D Group, while 640 were selected for the Control Group. A more conservative NS approach was registered in the 3D Group (full NS 20.6% vs 12.7%; intermediate NS 38.1% vs 38.0%; standard NS 41.2% vs 49.2%; p = 0.02). 3D Group patients had lower PSM rates (25 vs. 35.1%, p = 0.01). At MLR models, the availability of 3D technology (p = 0.005) and the absence of extracapsular extension (ECE, p = 0.004) at mp-MRI were independent predictors of lower PSMr. Moreover, 3D model represented a significant protective factor for PSM in patients with ECE or pT3 disease.
Conclusion: The availability of 3D models during the intervention allows to modulate the NS approach, limiting the occurrence of PSM, especially in patients with ECE at mp-MRI or pT3 PCa.
Metaverse surgical planning for robotic surgery: preliminary experience and users' perception.
Volpi G, Gatti C, Quara A, Piramide F, Amparore D, Alessio P Ther Adv Urol. 2024; 16:17562872241297524.
PMID: 39687329 PMC: 11648019. DOI: 10.1177/17562872241297524.
Metaverse in surgery - origins and future potential.
Checcucci E, Veccia A, Puliatti S, De Backer P, Piazza P, Kowalewski K Nat Rev Urol. 2024; .
PMID: 39349948 DOI: 10.1038/s41585-024-00941-4.
Ditonno F, Bologna E, Licari L, Franco A, Cannoletta D, Checcucci E Prostate Cancer Prostatic Dis. 2024; .
PMID: 39232095 DOI: 10.1038/s41391-024-00891-3.
Sarhan K, Khan N, Prezzi D, Antonelli M, Hyde E, MacAskill F J Robot Surg. 2024; 18(1):304.
PMID: 39105931 PMC: 11303509. DOI: 10.1007/s11701-024-02041-2.
Reitano G, Ceccato T, Botti S, Bruniera M, Carrozza S, Bovolenta E Cancers (Basel). 2024; 16(13).
PMID: 39001527 PMC: 11240638. DOI: 10.3390/cancers16132465.